State of New Jersey Common Pension Fund D lessened its stake in shares of BeiGene, Ltd. (NASDAQ:BGNE) by 5.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 46,010 shares of the company’s stock after selling 2,821 shares during the quarter. State of New Jersey Common Pension Fund D owned about 0.12% of BeiGene worth $4,760,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Aperio Group LLC purchased a new position in BeiGene during the 3rd quarter valued at about $301,000. First Trust Advisors LP grew its holdings in BeiGene by 17.0% during the 3rd quarter. First Trust Advisors LP now owns 57,142 shares of the company’s stock valued at $5,912,000 after buying an additional 8,282 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in BeiGene by 2.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,933 shares of the company’s stock valued at $4,272,000 after buying an additional 2,300 shares in the last quarter. State Street Corp grew its holdings in BeiGene by 14.4% during the 2nd quarter. State Street Corp now owns 36,604 shares of the company’s stock valued at $1,647,000 after buying an additional 4,619 shares in the last quarter. Finally, Hillhouse Capital Management Ltd. grew its holdings in BeiGene by 172.6% during the 2nd quarter. Hillhouse Capital Management Ltd. now owns 3,720,726 shares of the company’s stock valued at $167,433,000 after buying an additional 2,355,906 shares in the last quarter. 51.05% of the stock is owned by institutional investors and hedge funds.

BGNE has been the subject of a number of recent analyst reports. Robert W. Baird lifted their target price on BeiGene from $44.00 to $58.00 and gave the company an “outperform” rating in a report on Thursday, July 6th. Ladenburg Thalmann Financial Services assumed coverage on BeiGene in a report on Monday, August 7th. They set a “buy” rating and a $81.00 price objective for the company. Maxim Group boosted their price objective on BeiGene from $57.00 to $73.00 and gave the stock a “buy” rating in a report on Friday, July 7th. Morgan Stanley reissued an “overweight” rating and set a $83.00 price objective on shares of BeiGene in a report on Monday, July 10th. Finally, Zacks Investment Research raised BeiGene from a “sell” rating to a “buy” rating and set a $79.00 price objective for the company in a report on Tuesday, July 11th. Seven analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average target price of $92.50.

In related news, Director Bros. Advisors Lp Baker acquired 176,056 shares of the stock in a transaction dated Friday, August 11th. The stock was acquired at an average cost of $71.00 per share, with a total value of $12,499,976.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 19.90% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://theolympiareport.com/2017/11/02/beigene-ltd-bgne-holdings-trimmed-by-state-of-new-jersey-common-pension-fund-d.html.

BeiGene Profile

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016.

Want to see what other hedge funds are holding BGNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeiGene, Ltd. (NASDAQ:BGNE).

Institutional Ownership by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.